The launch of the Covid vaccine in the United States encounters an obstacle when the person gets sick after shooting

The first known allergic reaction to the Pfizer Covid-19 vaccine in the United States was reported in Alaska when some snarls began to surface in an attempt to send the shots across the country, highlighting the daunting future challenges for a historic immunization campaign. A health worker in Juneau, Alaska, with no history of allergies, experienced redness and shortness of breath 10 minutes after receiving an injection, the state health department said in a statement Wednesday.

The person was admitted to the emergency room and given Pepcid, Benadryl, and epinephrine through an intravenous drip. The patient stayed overnight and is in stable condition, according to the Alaska Department of Health.

Pfizer is coordinating with local officials, will closely monitor all reports suggesting severe allergic reactions, and will update the labeling language if necessary, spokeswoman Jerica Pitts said in a statement.

The incident came to light on Wednesday when the first hiccup in US vaccine distribution emerged, including a hold on delivery of 3,900 shots to two states and the announcement that Pfizer would provide about 900,000 fewer doses next week than than expected for shipping this week.

Pence to get vaccinated on Friday; Biden next week

Vice President Mike Pence will publicly receive the coronavirus vaccine on Friday, and President-elect Joe Biden is expected to be vaccinated as soon as next week amid concern that many Americans may refuse the injection. Meanwhile, California has reported more than 53,000 new coronavirus cases and 293 deaths.

Dear reader,

Business Standard has always worked hard to provide up-to-date information and commentary on developments that interest you and that have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our determination and commitment to these ideals. Even during these difficult times resulting from Covid-19, we continue to remain committed to keeping you informed and up to date with credible news, authoritative opinions and incisive commentary on relevant current issues.
However, we have a request.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to offer you more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. A higher subscription to our online content can only help us achieve our goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through multiple subscriptions can help us practice the journalism we’re committed to.

Support quality journalism e subscribe to Business Standard.

Digital editor